

contacting the test fluid sample with said monoclonal antibody,
and
detecting any complexes ~~form~~ formed from the binding of said 19P2
ligand with said monoclonal antibody, and
relating the ~~present~~ presence or amount of said complexes to the
~~present~~ presence or amount of 19P2 ligand in said sample.

4. (PREVIOUSLY PRESENTED) An isolated hybridoma cell
producing the monoclonal antibody as claimed in Claim 1.

5. (PREVIOUSLY PRESENTED) The monoclonal antibody of claim
1, which specifically binds with a peptide having the amino acid
sequence of SEQ ID NO: 11.

6. (CURRENTLY AMENDED) A method for detecting 19P2 ligand in
a sample, comprising:

contacting said sample with a monoclonal antibody of claim
5, and
detecting any complexes ~~form~~ formed from the binding of said
19P2 ligand to said monoclonal antibody, and
relating the ~~present~~ presence or amount of said complexes to
the ~~present~~ presence or amount of 19P2 ligand in said sample.

7. (PREVIOUSLY PRESENTED) The method of claim 6 further
comprising: assaying said sample wherein said 19P2 ligand is
attached to a carrier.

8. (PREVIOUSLY PRESENTED) The method of claim 6 wherein
said monoclonal antibody is attached to a carrier.

9. (PREVIOUSLY PRESENTED) The method of claim 6 wherein said monoclonal antibody is attached to a detectable signal or label.

10. (PREVIOUSLY PRESENTED) The method of claim 6 which is a sandwich assay.

11. (PREVIOUSLY PRESENTED) The method of claim 6 which is a competitive inhibition assay.

12. (PREVIOUSLY PRESENTED) The method of claim 6 in which the monoclonal antibody is P2L-1Ta as secreted by hybridoma NIBH 6300.

13. (CURRENTLY AMENDED) A method for detecting 19P2 ligand in a sample, comprising:

contacting said sample with the monoclonal antibody of claim 5 and a second antibody comprising an antibody which specifically binds to a peptide having the amino acid sequence of SEQ ID NO: 7, and

detecting any complexes ~~form~~ formed from the binding of the monoclonal antibody of claim 11, said 19P2 ligand and said second antibody, and

relating the ~~present~~ presence or amount of said complexes to the ~~present~~ presence or amount of 19P2 ligand in said sample.

14. (PREVIOUSLY PRESENTED) The monoclonal antibody of Claim 1, which specifically binds with a peptide having the amino acid sequence of SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:5 or SEQ ID NO:12.

15. (CURRENTLY AMENDED) The monoclonal antibody of claim 1, which specifically binds with a peptide having the amino acid sequence of amino acid residues 12 to 24 of ~~ex~~ SEQ ID NO:1, amino acid residues 12 to 24 of SEQ ID NO:2, or amino acid residues 12 to 24 of SEQ ID NO:3.

16. (PREVIOUSLY PRESENTED) The monoclonal antibody of claim 1, which specifically binds with a 19P2 ligand peptide, but which does not bind with a peptide having the amino acid sequence of SEQ ID NO:4 or SEQ ID NO:6.

17. (PREVIOUSLY PRESENTED) The monoclonal antibody of Claim 1 which is P2L-1Ta as secreted by hybridoma NIBH 6300.

18. (PREVIOUSLY PRESENTED) An isolated hybridoma cell line, having accession number NIBH 6300, said cell line producing the antibody P2L-1Ta.